Regulation of death and growth signals at the plasma membrane by sphingomyelin synthesis: Implications for hematological malignancies

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 3, 2011, Pages 324-333

  Lafont, Elodie ^a,b   Kitatani, Kazuyuki ^c   Okazaki, Toshiro ^d   Ségui, Bruno ^a,b  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c TOTTORI UNIVERSITY   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cancer; Cell death; Cell proliferation; Ceramide; Sphingolipids; Sphingomyelin synthase

Indexed keywords

AMIDE; CERAMIDE; DEATH RECEPTOR; EDELFOSINE; FAS LIGAND; JASPINE B; N (3 HYDROXY 1 HYDROXYMETHYL 3 PHENYLPROL)ALKANEAMIDE; SPHINGOMYELIN; SPHINGOMYELIN SYNTHASE 1; SPHINGOMYELIN SYNTHASE 2; SPHINGOSINE; SYNTHETASE; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RISK; CELL DEATH; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME STRUCTURE; GAUCHER DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; LEUKEMIA CELL; LIPID METABOLISM; LIPID RAFT; NONHUMAN; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STRESS;

ANIMALS; APOPTOSIS; CELL DEATH; CELL MEMBRANE; CELL PROLIFERATION; HEMATOLOGIC NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; SPHINGOMYELINS;

EID: 80052341977     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211796957801     Document Type: Article

References (81)

1. Hannun YA, Obeid LM. The Ceramide-centric universe of lipidmediated cell regulation: Stress encounters of the lipid kind. J Biol Chem 2002; 277(29): 25847-25850.
2. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science 1996; 274(5294): 1855-1859.
3. Segui B, Andrieu-Abadie N, Jaffrezou JP, Benoist H, Levade T. Sphingolipids as modulators of cancer cell death: Potential therapeutic targets. Biochim Biophys Acta 2006; 1758(12): 2104-2120.
4. Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Rep 2004; 5(8): 777-782.
5. Giussani P, Colleoni T, Brioschi L, Bassi R, Hanada K, Tettamanti G, et al. Ceramide traffic in C6 glioma cells: Evidence for CERTdependent and independent transport from ER to the Golgi apparatus. Biochim Biophys Acta 2008;1781(1/2):40-51.
6. Huitema K, van den Dikkenberg J, Brouwers JF, Holthuis JC. Identification of a family of animal sphingomyelin synthases. Embo J 2004; 23(1): 33-44.
7. Yamaoka S, Miyaji M, Kitano T, Umehara H, Okazaki T. Expression cloning of a human cDNA restoring sphingomyelin synthesis and cell growth in sphingomyelin synthase-defective lymphoid cells. J Biol Chem 2004; 279(18): 18688-18693.
8. Ullman MD, Radin NS. The enzymatic formation of sphingomyelin from ceramide and lecithin in mouse liver. J Biol Chem 1974; 249(5): 1506-1512.
9. Sabourdy F, Kedjouar B, Sorli SC, Colie S, Milhas D, Salma Y, et al. Functions of sphingolipid metabolism in mammals-lessons from genetic defects. Biochim Biophys Acta 2008; 1781(4): 145-183.
10. de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Haussinger D, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 2006; 36(1): 53-58.
11. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4(8): 604-616.
12. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010; 10(7): 489-503.
13. Uttam, S.K., Rizwan, M. Compositions and methods of sphingosine kinase inhibitors in radiation therapy of various cancers. US20100331393 (2010).
14. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9(2): 139-150.
15. Dagan, A., Gatt, S. Sphingolipids. US6756504 (2004).
16. Granot T, Milhas D, Carpentier S, Dagan A, Segui B, Gatt S, et al. Caspase-dependent and -independent cell death of Jurkat human leukemia cells induced by novel synthetic ceramide analogs. Leukemia 2006; 20(3): 392-399.
17. Wanebo, H.J., Mehta, S. Combinations of ceramide and chemotherapeutic agents for inducing tumor cell death. US7015251 (2006).
18. Wanebo, H.J. Combination of ceramide and gemcitabine for inducing cell death and uses thereof in treting cancer. US20090246271 (2009).
19. Wanebo, H.J., Mehta, S. Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer. US7820718 (2010).
20. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 2002; 110(1): 3-8.
21. Saddoughi SA, Song P, Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 2008; 49: 413-440.
22. Itoh M, Kitano T, Watanabe M, Kondo T, Yabu T, Taguchi Y, et al. Possible role of ceramide as an indicator of chemoresistance: Decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res 2003; 9(1): 415-423.
23. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, et al. Epithelial-mesenchymal and mesenchymalepithelial transitions in carcinoma progression. J Cell Physiol 2007; 213(2): 374-383.
24. Guan F, Handa K, Hakomori SI. Specific glycosphingolipids mediate epithelial-to-mesenchymal transition of human and mouse epithelial cell lines. Proc Natl Acad Sci USA 2009; 106(18): 7461-7466.
25. Siskind LJ. Mitochondrial ceramide and the induction of apoptosis. J Bioenerg Biomembr 2005;37(3):143-153.
26. van Blitterswijk WJ, van der Luit AH, Veldman RJ, Verheij M, Borst J. Ceramide: Second messenger or modulator of membrane structure and dynamics? Biochem J 2003; 369(Pt 2): 199-211.
27. Segui B, Legembre P. Redistribution of CD95 into the lipid rafts to treat cancer cells? Recent Pat Anticancer Drug Discov 2010; 5(1): 22-28.
28. Voelker DR, Kennedy EP. Cellular and enzymic synthesis of sphingomyelin. Biochemistry 1982; 21(11): 2753-2759.
29. Kitatani K, Idkowiak-Baldys J, Hannun YA. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal 2008; 20(6): 1010-1018.
30. Hanada K, Kumagai K, Yasuda S, Miura Y, Kawano M, Fukasawa M, et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature 2003; 426(6968): 803-809.
31. Tafesse FG, Ternes P, Holthuis JC. The multigenic sphingomyelin synthase family. J Biol Chem 2006; 281(40): 29421-29425.
32. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 1994; 269(5): 3125-3128.
33. Luberto C, Stonehouse MJ, Collins EA, Marchesini N, El-Bawab S, Vasil AI, et al. Purification, characterization, and identification of a sphingomyelin synthase from Pseudomonas aeruginosa. PlcH is a multifunctional enzyme. J Biol Chem 2003; 278(35): 32733-32743.
34. Fukasawa M, Nishijima M, Itabe H, Takano T, Hanada K. Reduction of sphingomyelin level without accumulation of ceramide in Chinese hamster ovary cells affects detergent-resistant membrane domains and enhances cellular cholesterol efflux to methyl-beta -cyclodextrin. J Biol Chem 2000; 275(44): 34028-34034.
35. Jin ZX, Huang CR, Dong L, Goda S, Kawanami T, Sawaki T, et al. Impaired TCR signaling through dysfunction of lipid rafts in sphingomyelin synthase 1 (SMS1)-knockdown T cells. Int Immunol 2008; 20(11): 1427-1437.
36. Vacaru AM, Tafesse FG, Ternes P, Kondylis V, Hermansson M, Brouwers JF, et al. Sphingomyelin synthase-related protein SMSr controls ceramide homeostasis in the ER. J Cell Biol 2009; 185(6): 1013-1027.
37. Ternes P, Brouwers JF, van den Dikkenberg J, Holthuis JC. Sphingomyelin synthase SMS2 displays dual activity as ceramide phosphoethanolamine synthase. J Lipid Res 2009; 50(11): 2270-2277.
38. Watanabe M, Kitano T, Kondo T, Yabu T, Taguchi Y, Tashima M, et al. Increase of nuclear ceramide through caspase-3-dependent regulation of the sphingomyelin cycle in Fas-induced apoptosis. Cancer Res 2004; 64(3): 1000-1007.
39. Albi E, Magni MV. Sphingomyelin synthase in rat liver nuclear membrane and chromatin. FEBS Lett 1999; 460(2): 369-372.
40. Kim CA, Bowie JU. SAM domains: Uniform structure, diversity of function. Trends Biochem Sci 2003; 28(12): 625-628.
41. Yeang C, Varshney S, Wang R, Zhang Y, Ye D, Jiang XC. The domain responsible for sphingomyelin synthase (SMS) activity. Biochim Biophys Acta 2008; 1781(10): 610-617.
42. Tani M, Kuge O. Sphingomyelin synthase 2 is palmitoylated at the COOH-terminal tail, which is involved in its localization in plasma membranes. Biochem Biophys Res Commun 2009; 381(3): 328-332.
43. Miro-Obradors MJ, Osada J, Aylagas H, Sanchez-Vegazo I, Palacios-Alaiz E. Microsomal sphingomyelin accumulation in thioacetamide-injured regenerating rat liver: Involvement of sphingomyelin synthase activity. Carcinogenesis 1993; 14(5): 941-946.
44. Luberto C, Hannun YA. Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. Does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C? J Biol Chem 1998; 273(23): 14550-14559.
45. Riboni L, Viani P, Bassi R, Giussani P, Tettamanti G. Basic fibroblast growth factor-induced proliferation of primary astrocytes. Evidence for the involvement of sphingomyelin biosynthesis. J Biol Chem 2001; 276(16): 12797-12804.
46. Tafesse FG, Huitema K, Hermansson M, van der Poel S, van den Dikkenberg J, Uphoff A, et al. Both sphingomyelin synthases SMS1 and SMS2 are required for sphingomyelin homeostasis and growth in human HeLa cells. J Biol Chem 2007; 282(24): 17537-17547.
47. Villani M, Subathra M, Im YB, Choi Y, Signorelli P, Del Poeta M, et al. Sphingomyelin synthases regulate production of diacylglycerol at the Golgi. Biochem J 2008; 414(1): 31-41.
48. Taguchi Y, Kondo T, Watanabe M, Miyaji M, Umehara H, Kozutsumi Y, et al. Interleukin-2-induced survival of natural killer (NK) cells involving phosphatidylinositol-3 kinase-dependent reduction of ceramide through acid sphingomyelinase, sphingomyelin synthase, and glucosylceramide synthase. Blood 2004; 104(10): 3285-3293.
49. Gouaze-Andersson V, Cabot MC. Glycosphingolipids and drug resistance. Biochim Biophys Acta 2006; 1758(12): 2096-2103.
50. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007; 11(6): 498-512.
51. Merrill AH, Jr., Jones DD. An update of the enzymology and regulation of sphingomyelin metabolism. Biochim Biophys Acta 1990; 1044(1): 1-12.
52. Milhas D, Clarke CJ, Hannun YA. Sphingomyelin metabolism at the plasma membrane: Implications for bioactive sphingolipids. FEBS Lett 2009; 584(9): 1887-1894.
53. Lafont E, Milhas D, Carpentier S, Garcia V, Jin ZX, Umehara H, et al. Caspase-mediated inhibition of sphingomyelin synthesis is involved in FasL-triggered cell death. Cell Death Differ 2010; 17(4): 642-654.
54. Bourteele S, Hausser A, Doppler H, Horn-Muller J, Ropke C, Schwarzmann G, et al. Tumor necrosis factor induces ceramide oscillations and negatively controls sphingolipid synthases by caspases in apoptotic Kym-1 cells. J Biol Chem 1998; 273(47): 31245-31251.
55. Separovic D, Hanada K, Maitah MY, Nagy B, Hang I, Tainsky MA, et al. Sphingomyelin synthase 1 suppresses ceramide production and apoptosis post-photodamage. Biochem Biophys Res Commun 2007; 358(1): 196-202.
56. Separovic D, Semaan L, Tarca AL, Awad Maitah MY, Hanada K, Bielawski J, et al. Suppression of sphingomyelin synthase 1 by small interference RNA is associated with enhanced ceramide production and apoptosis after photodamage. Exp Cell Res 2008; 314(8): 1860-1868.
57. Charruyer A, Bell SM, Kawano M, Douangpanya S, Yen TY, Macher BA, et al. Decreased Ceramide Transport Protein (CERT) Function Alters Sphingomyelin Production following UVB Irradiation. J Biol Chem 2008; 283(24): 16682-16692.
58. Ouasti S, Matarrese P, Paddon R, Khosravi-Far R, Sorice M, Tinari A, et al. Death receptor ligation triggers membrane scrambling between Golgi and mitochondria. Cell Death Differ 2007; 14(3): 453-461.
59. Lagace TA, Miller JR, Ridgway ND. Caspase processing and nuclear export of CTP: Phosphocholine cytidylyltransferase alpha during farnesol-induced apoptosis. Mol Cell Biol 2002; 22(13): 4851-4862.
60. Higa, T., Tanaka, J., Garcia-Gravalos, D. Oxy- and aminosubstituted tetrahydrofuryl derivatives with antitumour activity. US6864283 (2005).
61. Salma Y, Lafont E, Therville N, Carpentier S, Bonnafe MJ, Levade T, et al. The natural marine anhydrophytosphingosine, Jaspine B, induces apoptosis in melanoma cells by interfering with ceramide metabolism. Biochem Pharmacol 2009; 78(5): 477-485.
62. Kobayashi, S., Hanada, K. Sphingolipid synthesis inhibitor. US6888015 (2005).
63. Hanada, K., Nishijima, M., Kumagai, K. Drug promoting ceramide transport, base sequence for producing the drug, method of measuring activity of promoting ceramide release and method of measuring activity of promoting intermembrane ceramide transfer. US20080085859 (2008).
64. Schutze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Kronke M. TNF activates NF-kappa B by phosphatidylcholinespecific phospholipase C-induced acidic sphingomyelin breakdown. Cell 1992; 71(5): 765-776.
65. Wiegmann K, Schutze S, Machleidt T, Witte D, Kronke M. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 1994; 78(6): 1005-1015.
66. Cifone MG, Roncaioli P, De Maria R, Camarda G, Santoni A, Ruberti G, et al. Multiple pathways originate at the Fas/APO-1 (CD95) receptor: Sequential involvement of phosphatidylcholinespecific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. Embo J 1995; 14(23): 5859-5868.
67. Machleidt T, Kramer B, Adam D, Neumann B, Schutze S, Wiegmann K, et al. Function of the p55 tumor necrosis factor receptor death domain mediated by phosphatidylcholine-specific phospholipase C. J Exp Med 1996; 184(2): 725-733.
68. Meier, G.P., Bai, A., Zhou, D. Site and rate selective prodrug formulations of D609 with antioxidant and anticancer activity. US20070244076 (2007).
69. Thon L, Mohlig H, Mathieu S, Lange A, Bulanova E, Winoto-Morbach S, et al. Ceramide mediates caspase-independent programmed cell death. Faseb J 2005; 19(14): 1945-1956.
70. Porn-Ares MI, Chow SC, Slotte JP, Orrenius S. Induction of apoptosis and potentiation of TNF- and Fas-mediated apoptosis in U937 cells by the xanthogenate compound D609. Exp Cell Res 1997; 235(1): 48-54.
71. Zhang L, Shimizu S, Tsujimoto Y. Two distinct Fas-activated signaling pathways revealed by an antitumor drug D609. Oncogene 2005; 24(18): 2954-2962.
72. Yang Z, Khoury C, Jean-Baptiste G, Greenwood MT. Identification of mouse sphingomyelin synthase 1 as a suppressor of Baxmediated cell death in yeast. FEMS Yeast Res 2006; 6(5): 751-762.
73. Kilkus JP, Goswami R, Dawson SA, Testai FD, Berdyshev EV, Han X, et al. Differential regulation of sphingomyelin synthesis and catabolism in oligodendrocytes and neurons. J Neurochem 2008; 106(4): 1745-1757.
74. Van der Luit AH, Budde M, Zerp S, Caan W, Klarenbeek JB, Verheij M, et al. Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesteroldeficiency in lipid rafts. Biochem J 2007; 401(2): 541-549.
75. Veldman, R.J., Van Blitterswijk, W.J., Verheij, M., Koning, G.A. Pharmaceutical formulations employing short-chain sphingolipids and their use. WO2005046637 (2005).
76. Modrak, D. Sphingomyelin enhancement of tumor therapy. US6541462 (2003).
77. van Blitterswijk WJ, Klarenbeek JB, van der Luit AH, Alderliesten MC, van Lummel M, Verheij M. Fas/CD95 down-regulation in lymphoma cells through acquired alkyllysophospholipid resistance: Partial role of associated sphingomyelin deficiency. Biochem J 2010; 425(1): 225-234.
78. Miyaji M, Jin ZX, Yamaoka S, Amakawa R, Fukuhara S, Sato SB, et al. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J Exp Med 2005; 202(2): 249-259.
79. Huang CR, Jin ZX, Dong L, Tong XP, Yue S, Kawanami T, et al. Cisplatin augments FAS-mediated apoptosis through lipid rafts. Anticancer Res 2010; 30(6): 2065-2072.
80. Ding T, Li Z, Hailemariam T, Mukherjee S, Maxfield FR, Wu MP, et al. SMS overexpression and knockdown: Impact on cellular sphingomyelin and diacylglycerol metabolism, and cell apoptosis. J Lipid Res 2008; 49(2): 376-385.
81. Hailemariam TK, Huan C, Liu J, Li Z, Roman C, Kalbfeisch M, et al. Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation. Arterioscler Thromb Vasc Biol 2008; 28(8): 1519-1526.